Effects of cannabidiol on symptoms in people at clinical high risk for psychosis
These data provide the first evidence that CBD can ameliorate symptoms in the CHR [clinical high risk for psychosis] population. We found that treatment with CBD for three weeks was accompanied by a reduction in the severity of CHR symptoms and the distress associated with psychotic experiences. As we did not find an effect of CBD on the STAI-S score, these effects were unlikely to be driven by a reduction in state anxiety.
Recent meta-analyses suggest that existing pharmacological and psychological treatments have little effect on symptoms or the incidence of psychosis in CHR subjects, and there is currently no licensed treatment for this population.
Consistent with previous evidence, the incidence of adverse effects in the CBD-treated group was not different from the placebo-treated group, making CBD a good candidate treatment for CHR subjects. No subject dropped out of the CBD arm.
Read more at: https://doi.org/10.1002/wps.21253